Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Jun 21, 2023 (filed on Jun 23, 2023)Insider Name:Robertson Judith J.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,500Price:--
-
Jun 21, 2023 (filed on Jun 23, 2023)Insider Name:Maderis Gail JOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,500Price:--
-
Jun 21, 2023 (filed on Jun 23, 2023)Insider Name:Garcia Peter SOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,500Price:--
-
Jun 21, 2023 (filed on Jun 23, 2023)Insider Name:Farfel Gail MOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,500Price:--
-
Jun 21, 2023 (filed on Jun 23, 2023)Insider Name:Blaschke Terrence FOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,500Price:--
-
Jun 21, 2023 (filed on Jun 23, 2023)Insider Name:Azab MohammadOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,500Price:--
Filings by filing date
-
Jun 21, 2023 (filed on Jun 23, 2023)Insider Name:Robertson Judith J.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,500Price:--
-
Jun 21, 2023 (filed on Jun 23, 2023)Insider Name:Maderis Gail JOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,500Price:--
-
Jun 21, 2023 (filed on Jun 23, 2023)Insider Name:Garcia Peter SOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,500Price:--
-
Jun 21, 2023 (filed on Jun 23, 2023)Insider Name:Farfel Gail MOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,500Price:--
-
Jun 21, 2023 (filed on Jun 23, 2023)Insider Name:Blaschke Terrence FOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,500Price:--
-
Jun 21, 2023 (filed on Jun 23, 2023)Insider Name:Azab MohammadOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,500Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 10240 Bubb Road CUPERTINO CA 95014 |
Tel: | 1-646-3782928 |
Website: | https://www.durect.com |
IR: | See website |
Key People | ||
James E. Brown President, Chief Executive Officer, Director | Timothy M. Papp Chief Financial Officer, Company Secretary | Judy R. Joice Senior Vice President - Operations and Corporate Quality Assurance | Norman L. Sussman Chief Medical Officer |
Business Overview |
Durect Corporation is a biopharmaceutical company that is focused on advancing lifesaving investigational therapies. The Company's product candidates include DUR-928 oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. The Company's other commercial product candidates include POSIMIR, PERSERIS and Methydur Sustained Release Capsules. The Company is conducting a Phase IIb study (AHFIRM) of larsucosterol (DUR-928) in subjects with alcohol-associated hepatitis (Alcoholic Hepatitis (AH) to evaluate the safety and efficacy of larsucosterol treatment. Larsucosterol (DUR-928) is lead product candidate, an endogenous sulfated oxysterol and an epigenetic regulator. The Company focuses on drug delivery technology around its SABER and CLOUD Bioerodible Injectable Depot Systems. SABER uses a high viscosity base component, such as sucrose acetate isobutyrate (SAIB), to provide controlled release of a drug. CLOUD is a class of bioerodible injectable depot technology. |
Financial Overview |
For the fiscal year ended 31 December 2023, DURECT Corp revenues decreased 56% to $8.5M. Net loss decreased 22% to $27.6M. Revenues reflect Collaborative research and development decrease of 83% to $2.3M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.55 to -$1.05. |
Employees: | 72 as of Sep 30, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $26.95M as of Dec 31, 2023 |
Annual revenue (TTM): | $8.55M as of Dec 31, 2023 |
EBITDA (TTM): | -$36.73M as of Dec 31, 2023 |
Net annual income (TTM): | -$27.62M as of Dec 31, 2023 |
Free cash flow (TTM): | N/A |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 29,828,891 as of Dec 31, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |